Jump to content

Cynvenio Biosystems (new breakthru's in cancer diagnostics via liquid biopsy)

Recommended Posts



Basically, it's a new blood panel that employs Cynvenio's technology. Currently, it's a bit limited (how and why? watch video or listen to podcast), but there seems to be potential for the "real deal" (as Cramer in the CNBC video puts it).
The company says they are willing to partner up
third parties to make technology more accessible. Does this mean
Wal-Mart will one day have a LB unit along with the other low-cost
medical services they offer?

Some media stuff:

CNBC's Mad Money with Jim Cramer: Thermo Fisher Scientific CEO - Under
The Microscope


More videos: http://www.liquidbiopsy.com/videos/

On BioTech Nation (July 12, 2016), looking for cancer cells in the
blood. Dr. Paul Dempsey, Chief Scientific Officer of Cynvenio Biosystems
talks about their technology and an ongoing clinical study of women with
breast cancer. Listen to the interview:









Excerpt from Personalized Medicine in Oncology (PMO)
June 2016, Vol. 5, No. 5

Cynvenio is a cancer diagnostics company offering their LiquidBiopsy
technology to provide molecular analysis of cancer biomarkers in blood.
The company purports that molecular diagnostic approaches to cancer
detection and monitoring can benefit from their multiple-template
strategy that analyzes DNA from circulating tumor cells (ctcDNA) and
circulating cell-free DNA (ccfDNA) in blood, as well as from tissue
biopsies. They recently published the results from their National Cancer
Institute–supported clinical trial showing that data gained through
next-generation sequencing of ccfDNA and ctcDNA liquid biopsy templates
differ but complement each other and should be considered
simultaneously. Analysis of each template enables the capture of
different moments in a tumor’s evolution, providing additional and
complementary information to that acquired through tissue biopsy alone.
Moreover, the information gained from examining circulating tumor cells
(CTCs) enables the identification of both relevant mutations and other
biomarkers (such as proteins and RNA expression) that can drive a
particular cancer.

Tumor-derived samples from tissue biopsy, CTC populations, and ccfDNA
represent different moments in a cancer’s progression and may not derive
from the same biologic sources. Research suggests that ccfDNA samples
genomic DNA fragments released from all tumor sites and may capture
mutations not specifically associated with the disease, as well as
disease-relevant ones. In contrast, CTCs reflect the mobile subset of
tumor cells in blood; they are clearly related to the disease process
and predict more aggressive as well as metastatic disease.

Cynvenio is applying their multiple- template approach in a new clinical
research study in triple-negative breast cancer. To date, they have
enrolled 150 women. Enrollment is still open.

The publishers of PMO had the pleasure of speaking with Drs Dempsey and
Song about their multiple-template strategy that analyzes ctcDNA and
ccfDNA in blood as well as the initiation of their clinical trial in
triple-negative breast cancer.



Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...